spirapril

Ligand id: 6575

Name: spirapril

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 146.54
Molecular weight 466.16
XLogP 5
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of hypertension and congestive heart failure. Marketing authorisation by the US FDA has been discontinued. There is no information regarding approval for clinical use of this drug on the European Medicines Agency website. Other national approval agencies may continue to grant marketing authorisation.
Mechanism Of Action and Pharmacodynamic Effects
Metabolised to the active form spiraprilat, which inhibits angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. This in turn reduces the vasoconstrictive effects of angiotensin II leading to a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms leading to decreased vasopressor activity and decreased aldosterone secretion.